Serum Lactate in Acute Mesenteric Ischemia

Mesenteric Ischemia Clinical Trial

Official title:

Lactate Dehydrogenase, Bowel Necrosis and Mortality in Acute Mesenteric Ischemia: Retrospective Cross-Sectional

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04671979
• Other study ID #: DVO005-1-431-CEI969
• Status: Completed
• Start date: May 2, 2017
• Est. completion date: June 30, 2020

Study information

• Verified date: December 2020
• Source: Universidad del Rosario
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Background: Acute mesenteric ischemia is a vascular emergency with high mortality because of ambiguous symptomatology and a lack of early diagnostic markers. Lactate dehydrogenase has been described as a mortality biomarker and bowel necrosis length too. Nevertheless, the association between them has been mildly studied. Our objective was to evaluate the association between serum lactate admission levels, bowel necrosis extension, and mortality. Additionally, we performed a mortality characterization.

Materials and Methods: A retrospective cross-sectional study was designed. We reviewed patients' clinical records with acute mesenteric ischemia that attended a hospital between 2012 and 2018. We compared serum lactate admission levels with bowel necrosis length and mortality. A receiver operating characteristic curve was performed on the last association. As post hoc analysis, a classification and regression tree on mortality was fitted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: June 30, 2020
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Older than 18 years of age

• Required urgent laparotomy with a postoperative diagnosis of acute mesenteric ischemia

• Attended the private academic hospital, between 2012 and 2018

• Had a registered serum lactate dehydrogenase at admission

Exclusion Criteria:

• Secondary causes of AMI

• Chronic intestinal ischemic

• Patient records with no description of the serum lactate dehydrogenase or extension of intestinal necrosis

Related Conditions & MeSH terms

• Ischemia
• Mesenteric Ischemia

Intervention

Diagnostic Test:
• Lactate Dehydrogenase
All the patients that arrived at the hospital with symptoms of mesenteric ischemia, had a registered lactate dehydrogenase. We compared the value with the patient's outcomes.

Locations

Country	Name	City	State
Colombia	Andres Isaza Restrepo	Bogotá	Cundinamarca

Sponsors (1)

Lead Sponsor	Collaborator
Universidad del Rosario

Country where clinical trial is conducted

Colombia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum Lactate in mmol/l		30 days
Primary	Bowel necrosis length in cm		30 days
Primary	Percentage of patients that died between 30 postsurgical days, %		30 days
Secondary	Cut value of lactate levels as a predictor of mortality, in mmol/l	A receiver operating characteristics curve	30 days